Avalyn Pharma宣布,关于其吸入性吡非尼酮(AP01)用于治疗肺纤维化的更多长期研究数据,将于2026年欧洲风湿病联盟大会上公布。这些数据有望进一步验证该疗法的长期疗效与安全性。
Avalyn Pharma宣布,关于其吸入性吡非尼酮(AP01)用于治疗肺纤维化的更多长期研究数据,将于2026年欧洲风湿病联盟大会上公布。这些数据有望进一步验证该疗法的长期疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.